HCA Healthcare vs Tenet Healthcare
HCA and THC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCA and THC compare
HCA Healthcare is the larger company, worth 4.7 times as much as Tenet Healthcare ($102B against $22.0B).
On earnings, Tenet Healthcare is cheaper: it trades at 7.9× trailing earnings, against 15.7× for HCA Healthcare.
Tenet Healthcare grew revenue faster over the last twelve months (6.2% versus 5.8% for HCA Healthcare).
HCA Healthcare pays a dividend yielding 0.65%; Tenet Healthcare does not pay one.
Tenet Healthcare scores higher on the StockData Score (13 against 10 for HCA Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCA | THC |
|---|---|---|
| Size and price | ||
| Market cap | $102B | $22.0B |
| Share price | $473.19 | $273.25 |
| Change, 1 year | 1.0% | 30.7% |
| Change, 5 years | 90.6% | 262% |
| Beta (5Y) | 0.74 | 1.15 |
| Employees | 320K | 100K |
| StockData Score | ||
| Total score | 10 | 13 (better) |
| Valuation score | 2 | 5 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 4 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 15.7× | 7.9× (better) |
| P/S | 1.3× | 1.0× (better) |
| P/B | – | 4.0× |
| EV/EBITDA | 9.8× | 5.5× (better) |
| P/FCF | 17.2× | 6.6× (better) |
| PEG | 1.12 | 0.13 (better) |
| FCF yield | 5.8% | 15.1% (better) |
| Fair value | $480.11 | $449.89 |
| Margin of safety | 1.4% | 39.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.8% | 6.2% (better) |
| Revenue growth, 5Y average | 8.0% (better) | 3.9% |
| Net income growth (TTM) | 6.8% | – |
| EPS growth (TTM) | 16.7% | 136% (better) |
| EPS growth, 5Y average | 21.0% | 32.8% (better) |
| Profitability | ||
| Operating margin | – | 24.4% |
| Net margin | 8.6% | – |
| FCF margin | 7.6% | 15.0% (better) |
| Return on invested capital | – | 28.2% |
| Financial health | ||
| Debt / equity | – | 2.43 |
| Net debt / EBITDA | 3.11 | 1.68 (better) |
| Interest coverage | – | 6.6× |
| Current ratio | 0.82 | 1.58 (better) |
| Altman Z-score | 1.91 | 2.29 (better) |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Dividend yield | 0.65% | – |
| Payout ratio | 10.1% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 46.3% | – |
| Buyback yield | 8.9% (better) | 8.2% |
| Shareholder yield | 9.6% (better) | 8.2% |
| Ownership | ||
| Held by institutions | 62.1% | 100% |
| Held by insiders | 44.4% | 0.96% |
| Insider net buying, 12 months | −$31.1M (better) | −$71.2M |
| Superinvestors holding | 3 (better) | 2 |
| Short interest, % of float | 4.1% | 2.3% |
Go deeper
- HCA stock overview
- HCA income statement
- HCA valuation and score
- THC stock overview
- THC income statement
- THC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.